Literature DB >> 25707978

The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.

Jennifer S Petschauer1, Andrew J Madden, Whitney P Kirschbrown, Gina Song, William C Zamboni.   

Abstract

Major advances in carrier-mediated agents, which include nanoparticles, nanosomes and conjugates, have revolutionized drug delivery capabilities over the past decade. While providing numerous advantages, such as greater solubility, duration of exposure and delivery to the site of action over their small-molecule counterparts, there is substantial variability in systemic clearance and distribution, tumor delivery and pharmacologic effects (efficacy and toxicity) of these agents. This review provides an overview of factors that affect the pharmacokinetics and pharmacodynamics of carrier-mediated agents in preclinical models and patients.

Entities:  

Keywords:  Doxil; S-CKD602; carrier-mediated agents; clearance; nanoparticles; pharmacokinetics

Mesh：

Substances：

Year:  2015        PMID： 25707978      PMCID： PMC4594874          DOI： 10.2217/nnm.14.179

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN： 1743-5889            Impact factor:   5.307


  51 in total

Review 1.  Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.

Authors:  Daryl C Drummond; Charles O Noble; Mark E Hayes; John W Park; Dmitri B Kirpotin
Journal:  J Pharm Sci       Date:  2008-11       Impact factor: 3.534

Review 2.  Pharmacokinetics and biodistribution of nanoparticles.

Authors:  Shyh-Dar Li; Leaf Huang
Journal:  Mol Pharm       Date:  2008-07-09       Impact factor: 4.939

Review 3.  Immunological properties of engineered nanomaterials.

Authors:  Marina A Dobrovolskaia; Scott E McNeil
Journal:  Nat Nanotechnol       Date:  2007-07-29       Impact factor: 39.213

Review 4.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.

Authors:  Marina A Dobrovolskaia; Parag Aggarwal; Jennifer B Hall; Scott E McNeil
Journal:  Mol Pharm       Date:  2008-05-30       Impact factor: 4.939

5.  Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).

Authors:  C Rochlitz; T Ruhstaller; S Lerch; C Spirig; J Huober; T Suter; M Bühlmann; M Fehr; A Schönenberger; R von Moos; R Winterhalder; D Rauch; A Müller; M Mannhart-Harms; R Herrmann; B Cliffe; M Mayer; K Zaman
Journal:  Ann Oncol       Date:  2010-07-01       Impact factor: 32.976

6.  Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.

Authors:  Huali Wu; Ramesh K Ramanathan; Beth A Zamboni; Sandra Strychor; Suresh Ramalingam; Robert P Edwards; David M Friedland; Ronald G Stoller; Chandra P Belani; Lauren J Maruca; Yung-Jue Bang; William C Zamboni
Journal:  J Clin Pharmacol       Date:  2012-02       Impact factor: 3.126

7.  Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer.

Authors:  M I Koukourakis; S Koukouraki; A Giatromanolaki; S C Archimandritis; J Skarlatos; K Beroukas; J G Bizakis; G Retalis; N Karkavitsas; E S Helidonis
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

8.  Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.

Authors:  W C Zamboni; S Strychor; L Maruca; S Ramalingam; B A Zamboni; H Wu; D M Friedland; R P Edwards; R G Stoller; C P Belani; R K Ramanathan
Journal:  Clin Pharmacol Ther       Date:  2009-08-12       Impact factor: 6.875

Review 9.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

10.  An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.

Authors:  Alberto Gabizon; Rut Isacson; Ora Rosengarten; Dina Tzemach; Hilary Shmeeda; Rama Sapir
Journal:  Cancer Chemother Pharmacol       Date:  2007-06-05       Impact factor: 3.333
View more
  16 in total

Review 1.  Quality-by-Design Concepts to Improve Nanotechnology-Based Drug Development.

Authors:  Meghana Rawal; Amit Singh; Mansoor M Amiji
Journal:  Pharm Res       Date:  2019-09-03       Impact factor: 4.200

2.  A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse.

Authors:  M D McSweeney; T Wessler; L S L Price; E C Ciociola; L B Herity; J A Piscitelli; W C Zamboni; M G Forest; Y Cao; S K Lai
Journal:  J Control Release       Date:  2018-06-05       Impact factor: 9.776

Review 3.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

Review 4.  Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.

Authors:  Andrew T Lucas; Lauren Sl Price; Allison Schorzman; William C Zamboni
Journal:  Nanomedicine (Lond)       Date:  2017-07-26       Impact factor: 5.307

5.  Employing bicontinuous-to-micellar transitions in nanostructure morphology for on-demand photo-oxidation responsive cytosolic delivery and off-on cytotoxicity.

Authors:  Sharan Bobbala; Sean D Allen; Sijia Yi; Michael Vincent; Molly Frey; Nicholas B Karabin; Evan A Scott
Journal:  Nanoscale       Date:  2020-03-05       Impact factor: 7.790

6.  Anticancer Activity of Thymoquinone Cubic Phase Nanoparticles Against Human Breast Cancer: Formulation, Cytotoxicity and Subcellular Localization.

Authors:  Mohammed M Mehanna; Rana Sarieddine; Jana K Alwattar; Racha Chouaib; Hala Gali-Muhtasib
Journal:  Int J Nanomedicine       Date:  2020-12-01

7.  Molecular Dynamics Studies of Poly(Lactic Acid) Nanoparticles and Their Interactions with Vitamin E and TLR Agonists Pam1CSK4 and Pam3CSK4.

Authors:  Simon Megy; Stephanie Aguero; David Da Costa; Myriam Lamrayah; Morgane Berthet; Charlotte Primard; Bernard Verrier; Raphael Terreux
Journal:  Nanomaterials (Basel)       Date:  2020-11-05       Impact factor: 5.076

Review 8.  In vivo methods for acute modulation of gene expression in the central nervous system.

Authors:  Andrzej W Cwetsch; Bruno Pinto; Annalisa Savardi; Laura Cancedda
Journal:  Prog Neurobiol       Date:  2018-04-22       Impact factor: 11.685

9.  Combination Chemotherapy with Cisplatin and Chloroquine: Effect of Encapsulation in Micelles Formed by Self-Assembling Hybrid Dendritic-Linear-Dendritic Block Copolymers.

Authors:  Rebeca González-Pastor; Alexandre Lancelot; Violeta Morcuende-Ventura; María San Anselmo; Teresa Sierra; José L Serrano; Pilar Martin-Duque
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

10.  Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors.

Authors:  Keith T Schmidt; Alwin D R Huitema; Thomas P C Dorlo; Cody J Peer; Lisa M Cordes; Linda Sciuto; Susan Wroblewski; Yves Pommier; Ravi A Madan; Anish Thomas; William D Figg
Journal:  Cancer Chemother Pharmacol       Date:  2020-09-08       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.